SBIR Phase I: EEG-guided intelligent transcranial photobiomodulation to reduce symptoms of autism

SBIR 第一阶段：脑电图引导的智能经颅光生物调节以减轻自闭症症状

• 批准号: 2136474
• 负责人: Eugenia Steingold
• 金额: $ 25.6万
• 依托单位: JELIKALITE LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-01 至 2023-01-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2136474&HistoricalAwards=false
• 关键词: SBIR; Phase; EEG; guided; intelligent

This Small Business Innovation Research (SBIR) Phase I project aims to demonstrate proof of concept for a wearable device for delivering personalized therapy to mitigate autism in children. One out of 44 children in America is diagnosed with autism. Behavioral therapies with no pharmacological or device treatments show mixed effects. This project advances an effective personalized treatment to augment or replace the state of practice. The device will be used in the privacy of each child’s home without the need for a specialist. The benefit of the proposed system is approximately 33% improvement in autism symptoms, resulting in over $1 million in lifetime savings for each child. This SBIR Phase I project aims to demonstrate the feasibility of a non invasive wearable medical device that stimulates brain tissue using near infrared radiation in Transcranial Photobiomodulation (tPBM), with integrated EEG feedback on Delta brain waves indicative of therapeutic effect. This project will complete prototyping of a system suitable for use, collect pre-clinical data in children, develop a signal analysis database, and develop algorithms based on the patient’s baseline factors for the desired effect.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I阶段项目旨在为可穿戴设备提供概念证明，以提供个性化治疗以减轻儿童的自闭症。美国44名儿童中有一个被诊断出患有自闭症。没有药理或设备治疗的行为疗法显示出混合作用。该项目可以进行有效的个性化治疗方法，以增加或替代实践状态。该设备将用于每个孩子的房屋的私密性，而无需专家。拟议系统的好处是自闭症症状改善了33％，为每个孩子节省了超过100万美元。该SBIR I期项目旨在证明非侵入性可穿戴医疗器械的可行性，该医疗器械在经颅光生物调节（TPBM）中使用近红外辐射刺激脑组织，并在三角洲脑波上进行了综合的EEG反馈，以表明具有治疗作用的三角洲脑波。该项目将完成适合使用的系统的原型制作，在儿童中收集临床前数据，开发信号分析数据库，并根据患者的基线因子的基线因子来开发算法。该奖项反映了NSF的法定任务，并被认为是通过基金会的知识分子和更广泛的影响来评估的珍贵的支​​持，并被视为珍贵的支持。